Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 279 for:    Genetic Diseases, Inborn AND Genome

NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03738098
Recruitment Status : Enrolling by invitation
First Posted : November 12, 2018
Last Update Posted : August 15, 2019
Sponsor:
Collaborators:
Albert Einstein College of Medicine
New York Genome Center
National Human Genome Research Institute (NHGRI)
National Institute on Minority Health and Health Disparities (NIMHD)
Information provided by (Responsible Party):
Icahn School of Medicine at Mount Sinai

Brief Summary:
The NYCKidSeq program will significantly advance the implementation of genomic medicine, particularly for children, young adults and their families in Harlem and the Bronx. The study will assess the clinical utility of genomic medicine in three broad areas of pediatric disorders, while engaging a range of providers and community advisors to overcome the well-documented barriers to inclusion of underserved and underrepresented populations in genomic research. The study will also include testing, analyzing, and implementing a novel communication tool, Genomic Understanding, Information and Awareness (GUÍA), to facilitate the return of genomic test results. The use of GUÍA will enhance the understanding of these genomic testing results by families, patients, and care providers at all levels of expertise, in two health systems. Healthcare system leadership will be engaged to provide insights into their readiness for genomic implementation. Overall, the NYCKidSeq program will inform the genomics and clinical communities about how to implement genomic medicine in a diverse population in a clinically useful, technologically savvy, culturally sensitive, and ethically sound manner.

Condition or disease Intervention/treatment Phase
Genetic Diseases, Inborn Genetic Predisposition to Disease Behavioral: Standard of Care Behavioral: GUÍA Not Applicable

Detailed Description:

NYCKidSeq is a research study using a randomized controlled trial (RCT) design to compare the use of GUÍA in a traditional genetic counseling return of results session to facilitate the return of genomic results compared to a traditional return of results counseling session. GUÍA will be an enhanced, personalized electronic version focused on helping patients understand their own genomic results. The researchers will also evaluate the clinical utility of whole genome sequencing (WGS) compared to targeted gene panels (TGP) in children with suspected genetic etiology of their neurologic disorders, primary immunodeficiencies, and cardiovascular disorders with the goal of detecting the mutated gene(s) responsible for their disorder.

1100 referred children Mount Sinai and Albert Einstein College of Medicine/Montefiore Hospital (Einstein/Montefiore) will be enrolled and randomized to either traditional genetic counseling (standard of care) or traditional genetic counseling plus GUÍA. The researchers will assess parents' perceived and subjective understanding of results as well as their adherence to follow-up recommendation (primary and secondary outcomes) through the use of parental surveys at three time points. The RCT will occur in the context of performing WGS and TGP for diagnostic purposes in 1,130 children.

Participants will have three study visits (Baseline, ROR1, and ROR2) over a nine-month period. At the baseline visit, families will receive pre-test counseling and will complete a survey. Blood will be collected from all study participants and from each biological parent (if available) to assist with interpretation of genomic results. Samples will undergo WGS and TGP. Approximately three months later, results will be returned and explained via one of the two study arms - traditional genetic counseling versus genetic counseling with GUÍA, and parents will be asked to complete the ROR1 survey. Six months later, they will be asked to complete the ROR2 survey. The length of a subject's participation will be a minimum of nine months to a maximum of 27 months, depending on the time of study entry; participation after the initial nine months will consist solely of chart and data review. Over the initial 9-month period the investigators are studying the experiences and understanding of parents of children who receive sequencing to help understand how best to implement genomic medicine in a diverse population.

GUÍA will be an enhanced, personalized electronic version of a flip chart, which is the type of tool most commonly used in routine genetic counseling. In the third year of the study, the study team anticipates to have the tool integrated into EPIC. There are no tools yet focused on this complex information, specifically on helping patients understand their own genomic results.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The overall design is a Randomized Controlled Trial (RCT), evaluating the use of a novel Communication Tool to facilitate the return of WGS genomic results and comparing it to return of results using routine genetic counseling. The RCT will occur in the context of the performing WGS and TGP for diagnostic purposes in 1,130 children in an effort to assess clinical utility. Children and young adults with specific disorders will be recruited from MS and EM. In the Traditional GC group, participants will receive traditional genetic counseling for the Baseline and Return of Results (ROR1) visits. In the Communication Tool group, they will receive traditional GC for the Baseline visit, and traditional GC plus Communication Tool for the ROR1 visit (see arm descriptions below). Based on the subjects' randomization, they will be scheduled to see a specific genetic counselor, as the genetic counselors will be assigned to a specific arm and will remain in that arm for the duration of the study.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children
Actual Study Start Date : January 30, 2019
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Traditional Genetic Counseling
Standard of care genetic counseling session
Behavioral: Standard of Care
Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
Other Name: Traditional Genetic Counseling

Experimental: GUÍA
Standard of care genetic counseling session with GUÍA.l
Behavioral: Standard of Care
Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
Other Name: Traditional Genetic Counseling

Behavioral: GUÍA
GUÍA for the ROR1 visit.
Other Name: Communication Tool




Primary Outcome Measures :
  1. Perceived understanding of genomic testing results [ Time Frame: 3 months ]
    Perceived understanding of genomic testing results. Scale from 1 (very little or none of it) to 5 (understood almost all or all of it) at 3 months

  2. Perceived understanding of genomic testing results [ Time Frame: 9 months ]
    Perceived understanding of genomic testing results. Scale from 1 (very little or none of it) to 5 (understood almost all or all of it) at 3 months

  3. Perceived confidence explaining genomic testing results [ Time Frame: 3 months ]
    Perceived confidence explaining child's genetic test results. Scale from 1 (completely confident) to 5 (not confident at all) at 3 months

  4. Perceived confidence explaining genomic testing results [ Time Frame: 9 months ]
    Perceived confidence explaining child's genetic test results. Scale from 1 (completely confident) to 5 (not confident at all) at 9 months


Secondary Outcome Measures :
  1. Objective understanding of genomic testing results [ Time Frame: 3 months ]
    Participants will answer yes, no, or not sure/don't remember at 3 months

  2. Objective understanding of genomic testing results [ Time Frame: 9 months ]
    Participants will answer yes, no, or not sure/don't remember at 9 months

  3. Understanding of recommended medical follow up and actionability of genomic results [ Time Frame: 3 months ]
    Participants will answer yes, no, or I don't know/don't remember/unsure

  4. Adherence to medical follow up recommendations [ Time Frame: 9 months ]
    Participants will answer yes, not yet but plan to; or no, and don't plan to; or don't know

  5. Percent of participants with definitive or likely positive diagnoses [ Time Frame: up to 27 months ]
    Diagnostic results assessed by percent of participants with definitive or likely positive diagnoses

  6. Time to diagnosis of WGS and TGP [ Time Frame: up to 27 months ]
    Time to diagnosis comparison of WGS and TGP

  7. Concordance of WGS and TGP results [ Time Frame: up to 27 months ]
    Percent of agreement between WGS and TGP testing results



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Infants, children and young adults up to and including 21 years of age; young adults (18-21) who are cognitively intact may participate in this study, but their parent(s) or legal guardian(s) must also agree to participate
  • English- or Spanish-speaking parent or legal guardian capable of providing informed consent, participating in surveys, and able to see Communication Tool
  • Currently undiagnosed, likely genetic* cause of neurologic, immunologic, or cardiac disorders (*as determined by disorder-specific criteria in Section IIIc. and phenotype checklist Appendix w.)
  • Followed by a physician in the MS or EM systems;
  • Willing and able to return for each study visit (not moving out of the area within nine months)
  • If targeted gene panels and/or whole exome sequencing were previously done, results must have been returned at least six months before enrollment;
  • If targeted gene panels and/or whole exome sequencing were previously done, results must have been negative, or identified only one variant in a potentially causative autosomal recessive gene, and
  • If the parents received genetic counseling about this child, themselves, or a family member, the last genetic counseling session must have been at least six months before enrollment (*if testing was within 6-months their recruitment will be held until they 6-months or after)
  • If patients have undergone karyotyping alone, we do not have to wait 6 months prior to inclusion.

Exclusion Criteria:

  • The referred child is currently participating in a different genetic sequencing study, and
  • The referred child has a known or likely molecular genetic diagnosis for their neurologic, immunologic, or cardiac disorder.
  • The referred child has had a bone-marrow transplant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03738098


Locations
Layout table for location information
United States, New York
Albert Einstein College of Medicine/Montefiore
Bronx, New York, United States, 10461
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Albert Einstein College of Medicine
New York Genome Center
National Human Genome Research Institute (NHGRI)
National Institute on Minority Health and Health Disparities (NIMHD)
Investigators
Layout table for investigator information
Principal Investigator: Eimear Kenny, PhD Icahn School of Medicine at Mount Sinai
Principal Investigator: Melissa Wasserstein, MD Albert Einstein College of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT03738098     History of Changes
Other Study ID Numbers: GCO 16-1731
U01HG009610 ( U.S. NIH Grant/Contract )
First Posted: November 12, 2018    Key Record Dates
Last Update Posted: August 15, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Icahn School of Medicine at Mount Sinai:
Whole Genome Sequencing
Genetic Counseling
Hereditary Childhood Disease
Genomic Medicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Genetic Diseases, Inborn
Disease Susceptibility
Genetic Predisposition to Disease
Disease Attributes
Pathologic Processes